Clinical Trials Directory

Trials / Completed

CompletedNCT00757744

Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
45 (actual)
Sponsor
Yale University · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

A randomized clinical trial evaluating the reduction of HIV risk behaviors and drug use when providing integrated behavioral drug and HIV risk reduction counseling (BDRC) along with methadone maintenance treatment in Wuhan, China

Detailed description

This project is a supplement to a parent grant, Drug Counseling and Abstinence-Contingent Take-Home Buprenorphine in Malaysia. The specific aims of the parent grant include evaluating whether the relatively minimal counseling and other services provided with standard buprenorphine maintenance treatment (Standard BUP) is sufficient or whether one or a combination of two enhanced behavioral treatments--behavioral drug and HIV risk reduction counseling (BDRC) or abstinence-contingent take-home buprenorphine (ACB)-improve its efficacy (Specific Aim 1) and are cost-effective, with regard to the direct economic costs of providing the treatments (Specific Aim 2) and also to provide training and mentoring in drug abuse treatment and HIV prevention research to clinical researchers and clinical training for health professionals in Malaysia (Specific Aim 4). BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in developing countries. The specific aims of the proposed study are consistent with the specific aims of the parent grant and include evaluating in a pilot, randomized clinical trial in a methadone treatment program in Wuhan, China, the feasibility and potential efficacy for reducing illicit drug use and HIV risk behaviors of BDRC when combined with standard methadone treatment services (Standard Methadone) compared to Standard Methadone only (Specific Aim 1 of the proposed study). Additional Specific Aims of the proposed study include developing estimates of the treatment costs and cost-effectiveness of Standard Methadone and BDRC (Specific Aim 2 of the proposes study), and providing training and mentoring in drug abuse treatment and HIV prevention research to clinical researchers an clinical training for health professionals in China (Specific Aim 3 of the proposed study). Specific aims of the China project: 1. Conduct a preliminary evaluation of the feasibility, acceptability, and preliminary efficacy for increasing treatment retention and reducing drug use and HIV risk behaviors of Behavioral Drug and HIV Risk Reduction Counseling (BDRC) when combined with Standard Methadone, in comparison to Standard Methadone, among opiate dependent treatment seeking volunteers admitted to the Wuhan Methadone Clinic. 2. Develop estimates of the costs and cost-effectiveness of Standard Methadone and BDRC. 3. Train and provide ongoing clinical supervision to a core group of 10 drug counseling staff and provide additional mentoring in drug abuse and HIV risk reduction research to investigators in China.

Conditions

Interventions

TypeNameDescription
BEHAVIORALBehavioral Drug and HIV Risk Reduction Counseling (BDRC)once weekly individual counseling
BEHAVIORALDrug counselingindividual drug counseling

Timeline

Start date
2007-09-01
Primary completion
2010-01-01
Completion
2010-09-01
First posted
2008-09-23
Last updated
2020-03-30

Locations

2 sites across 2 countries: United States, China

Source: ClinicalTrials.gov record NCT00757744. Inclusion in this directory is not an endorsement.